Citable filing context
MCK's research view summarizes recent SEC filing context, starting with earnings from Aug 5, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 5, 2026 | earnings | McKesson reported fiscal 2027 first quarter results with $105.4 billion in revenue and raised full-year adjusted EPS guidance. |
| Jul 24, 2026 | other | McKesson Corporation held its annual meeting of shareholders on July 22, 2026, to elect directors and ratify auditors. |
| Jul 1, 2026 | management_change | Thomas L. Rodgers announced his retirement, and Ramesh Srinivasan was appointed Chief Strategy Officer, effective August 1, 2026. |
| Aug 5, 2026 | Guidance: adjusted_earnings_per_diluted_share | 44.20 to 45.00 |
| May 7, 2026 | Guidance: adjusted_eps | 43.80 to 44.60 |
| May 7, 2026 | Guidance: adjusted_eps_growth | 13.00 to 16.00 |
| Aug 5, 2026 | mda_quarterly | McKesson Corporation reported an 8% revenue increase for the quarter ended June 30, 2026, driven by strong performance in its North American Pharmaceutical and Oncology & Multispecialty segments. Growth in North American Pharmaceutical was fueled by higher volumes from institutional and retail national accounts, while the Oncology & Multispecialty segment benefited from increased specialty pharmaceutical sales. Despite revenue growth, diluted earnings per share fell to $5.15 from $6.25, impacted by higher restructuring charges and increased operating expenses. The company is currently executing a strategic reorganization, including the planned separation of its Medical-Surgical Solutions segment. As part of this transition, Apollo Funds acquired a 13% minority interest in the segment for $1.25 billion. McKesson also initiated significant restructuring programs across its Corporate and Prescription Technology Solutions units to optimize operations, with total anticipated charges ranging from $430 million to $560 million. Liquidity remains robust, supported by a new $5 billion unsecured credit facility and $3.2 billion in proceeds from a syndicated term loan within the Medical-Surgical segment. The company continues to prioritize shareholder returns, repurchasing $2.5 billion in common stock during the quarter and increasing its quarterly dividend to $0.94 per share. |
| May 8, 2026 | business | McKesson Corporation is a diversified healthcare services leader operating through four key segments. The North American Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter drugs across the U.S. and Canada, serving pharmacies, hospitals, and manufacturers, and includes the ClarusONE sourcing joint venture. The Oncology & Multispecialty segment offers comprehensive solutions for oncology and other specialty practices, including specialty drug distribution, group purchasing organizations like Onmark, infusion services, and technology solutions via Ontada, while also supporting the U.S. Oncology Network and holding interests in PRISM Vision and SCRI. Prescription Technology Solutions addresses medication access, affordability, and adherence by connecting patients, pharmacies, providers, PBMs, and biopharma, offering services such as electronic prior authorization and price transparency, having saved patients billions. The Medical-Surgical Solutions segment supplies medical-surgical products and lab equipment to non-acute settings; however, McKesson intends to separate this segment into an independent company, with Apollo Funds acquiring a 13% minority stake for $1.25 billion. The company operates in highly competitive and regulated markets, with Cencora and Cardinal Health being primary competitors in distribution. |
Source: SEC EDGAR filing text and events; period Aug 5, 2026; filed Aug 5, 2026.
MCK company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.